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Treatment of RBCs with protease enzymes or dithiothreitol (DTT)
causes denaturation of several RBC antigens and is regularly used in
antibody identification. In this study, we have standardized enzyme
and DTT treatment of adherent RBCs in the magnetic-mixed
passive hemagglutination assay (M-MPHA) for antibody ident-
ification. We have also tried drying these treated RBCs. The optimal
enzyme and DTT treatment conditions for intact adherent RBCs
were determined, in addition to the optimal condition for drying
RBCs. All tested agents with the exception of chymotrypsin could
be applied to RBC drying, but the optimal condition for drying was
different from that for intact RBCs. Enzyme or DTT treatment of
adherent RBCs and their application in M-MPHA provide a simple
and convenient method for antibody identification. Furthermore,
the technique of drying treated RBCs provides an even stronger
antibody identification tool, since dried RBCs can be stored for a
long period. Immunohematology 2002;18:114–119.
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Treatment of RBCs with certain enzymes or
dithiothreitol (DTT) is useful for antibody
identification, but may cause denaturation of certain
RBC antigens.1 Variable results have been reported, i.e.,
some reports demonstrate antigen denaturation, others
report that antigens are unchanged.2 We believe this
variability occurs because RBCs are treated using
nonstandard methods.
Several new techniques, namely microcolumn
agglutination3 and solid phase red cell adherence
(SPRCA),4 have been used widely as alternatives to
conventional tube tests. These methods contribute to
simplification and automation of pretransfusion
testing. We have developed a variation of the solid
phase method, which we call the magnetic-mixed
passive hemagglutination assay (M-MPHA), which is a
modification of the mixed-passive hemagglutination
assay (MPHA).5,6
M-MPHA has high sensitivity and only a few falsely
positive reactions are seen. A more advanced
technique, M-MPHA-Dry,7 which uses dried RBCs
instead of intact RBCs, has an advantage over the
commonly used hemagglutination methods because
microplates containing dried RBCs can be stored for
long periods.
In the tube test, RBC treatment with enzymes or
DTT can be a complicated procedure. However,
treatment of RBCs adhering to microplate wells is easy
and convenient, since centrifugal washing is not
needed and the ratio of RBCs in the treatment agent
solution is always kept the same.
In this study, we standardized the treatment of
conventional or dried RBCs adhering to microplates
with various enzymes and DTT, which are commonly
used in serology, for the purpose of applying this
information to antibody identification by M-MPHA.
Materials and Methods
Enzymes and DTT 
Trypsin and chymotrypsin were obtained from
Sigma Chemical Co. (St Louis, Missouri). The enzyme
activity listed on the label was used for calculations in
this study. Enzyme concentrations were expressed in
units (U) per 50 µL. Papain (ID-Papain) and bromelin
(ID-Diluent 1) were obtained from DiaMed AG (Morat,
Switzerland), and the activity of these enzymes was
assayed by the casein method of Hagihara et al.8
Enzyme activities of ID-Papain (papain) and ID-Diluent
1 (bromelin) were determined to be 163 U and 86.5 U
per 50 µL, respectively. DTT was obtained from Wako
Junyaku (Osaka, Japan).
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Reagent RBCs
Group O reagent RBCs were obtained from Ortho-
Clinical Diagnostics (Raritan, NJ).
Antibodies
Human polyclonal reagent antibodies (anti-D, -E, -C,
-e, -c, -Fya, -Fyb, -S, -s, -Xga, -Jsb, -Kpa, -Kpb, -K, -k, -Jka, -Jkb, -
Lua, -Lub, -Dia, -Wra, and anti-HLA B7) were obtained from
Ortho-Clinical Diagnostics, Bio Test AG (Dreieich,
Germany), or Gamma Biologicals, Inc. (Houston,Texas).
Anti-M, -Lea, -Jra, -Rg, bromelin one-stage falsely positive
samples, and antibody-negative sera were obtained
from donors at the Tokyo Metropolitan Blood Center.
These samples were stored at –20°C until used.
M-MPHA
In the first step of M-MPHA, an intact RBC
monolayer is immobilized onto a microplate well.9
Adherent conventional RBCs are incubated with serum
antibodies. After washing, either anti-human IgG-
sensitized9 or anti-human IgM-sensitized10 indicator
magnetic particles are added to each microplate well to
detect IgG or IgM antibodies on the RBCs. The
microplate is then placed on a magnet plate to read the
results pattern. In a positive reaction, the indicator
magnetic particles are spread over the well; in a
negative reaction, they precipitate in the center of the
well. Anti-IgG-sensitized particles and anti-IgM-
sensitized particles were used for both M-MPHA and M-
MPHA-Dry methods. All IgG antibodies, which were
detected by either a conventional tube enzyme test or
an indirect antiglobulin test,were detected by M-MPHA
without using enzyme-treated RBCs.11
Treatment of adherent intact RBCs with DTT
RBCs were fixed to microplate wells according to
the method of Ohgama et al.9 Subsequently, 100 µL of
0.0015 M to 0.2 M DTT solutions,which were prepared
as serial master dilutions in phosphate buffered saline
(PBS) at pH 6, 7, and 8, respectively, were added to the
wells. After 30- to 60-minute incubations at room
temperature (RT) and at 37°C, plates were washed × 6
with saline. After washing, antisera and negative
control sera were tested using anti-IgG-sensitized
magnetic particles.9
Treatment of adherent intact RBCs with enzymes.
Various concentrations of trypsin (0 to 2560 U),
bromelin (0 to 17 U), papain (0 to 30 U), and
chymotrypsin (0 to 66 U) per 50 µL were prepared by
serial master dilutions with PBS at pH 6, 7, and 8.
Chymotrypsin solution was also prepared with a LISS
plus glycine solution (Glycine-LISS) at pH 8. Fifty µL of
each enzyme solution was added to the microplate
wells with intact RBCs. The solutions were incubated
for 10 to 30 minutes at RT or at 37°C, and then plates
were washed × 6 with saline. After washing, antisera,
including various negative sera, were tested using anti-
IgG-sensitized magnetic particles.9
Enzyme-treated falsely positive samples
Nine bromelin-treated falsely positive samples
found through routine screening of healthy donors by
the bromelin one-stage technique were tested with
bromelin-treated RBCs by M-MPHA, at the optimal
condition of 2 U per 50 µL and pH 6, at RT for 10
minutes. The reactivity of the falsely positive samples
was tested with both anti-IgG9 and anti-IgM10
indicators. Bromelin-treated falsely positive sera are
those that react with reagent RBCs, including
autocontrols, but are nonreactive versus papain-treated
RBCs.
Drying of enzyme- or DTT-treated RBCs
Optimal conditions for RBC drying were evaluated
to develop an enzyme or DTT-treated M-MPHA-Dry.
After enzyme or DTT treatment, RBCs were lysed by
Triton X-100 and then dried in a vacuum according to
the method of Tamai et al.7 Reactivity of dried RBCs
treated under various enzyme and DTT conditions was
tested with the various antisera.
Results
Optimal DTT treatment conditions for M-MPHA
The reactivity of anti-K, -k, -Kpb, and -Jsb was not
reduced (compared to untreated RBCs) when the RBCs
were treated with DTT in PBS at pH 6, 7, or 8 for 30
minutes at RT. When RBCs were treated with DTT at
37°C for 30 minutes, reactions with all these antibodies
were eliminated at concentrations greater than 0.006
M only with PBS at pH 8. A few of the negative sera
showed a falsely positive reaction at concentrations
greater than 0.1 M DTT. Consequently, the optimal
condition was determined to be 0.0125 M DTT, at pH
8, at 37°C for 30 minutes. Under these conditions, the
reactions of DTT-treated RBCs with anti-K, -k, -Kpa, -Kpb,
and -Jsb were negative without falsely positive
reactions. Reactivity with anti-Lua and -Lub, however,
did not change (Table 1).
Optimal trypsin treatment conditions for M-MPHA
When RBCs were treated with trypsin in PBS at pH
8 for 10 minutes at RT, reactivity with anti-Lua, -Lub and
-M was eliminated at 1280 U, 320 U, and 1280 U per 50
µL, respectively. When RBCs were treated in PBS at pH
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8 for 30 minutes at 37°C, reactivity with anti-Lua, -Lub,
and -M was eliminated at 40 U, 40 U, and 320 U per 50
µL, respectively. Falsely positive reactions did not
occur until 2560 U. Consequently, the optimal
conditions were determined to be 320 U, at pH 8, at
37°C for 30 minutes. Under these conditions, trypsin-
treated RBCs were nonreactive not only with anti-Lua,
-Lub, and -M, but also with anti-Xga. The reactivities of
anti-Fya, -Fyb, -S, and -s did not change. In contrast,
reactivities with anti-D, -C, -E, -c, -e, -Jka, -Jkb, -Jra, -Wra, and
HLA-related antibodies increased (Table 1).
Optimal chymotrypsin treatment conditions for 
M-MPHA
The reactivity of chymotrypsin-treated RBCs with
anti-Fya, -Fyb, -M, -S, -s, and -Kpb was not eliminated
despite treatment at 66 U per 50 µL in PBS at pH 8 for
30 minutes at RT. Following treatment at 37°C for 30
minutes, however, chymotrypsin-treated RBCs were
nonreactive with anti-Fya and -S at 8 U and 16 U,
respectively, but reactivity with anti-M, -s and -Fyb was
not eliminated until 66 U, and falsely positive reactions
occurred at more than 66 U. After treatment at 37°C
for 60 minutes, reactivity with anti-Fya, -Fyb, and -S was
eliminated at 4U, 33U, and 8U per 50 µL, respectively,
but reactivity with anti-M and -s was not eliminated.
RBCs that were treated with chymotrypsin in Glycine-
LISS at pH 8 for 30 minutes at 37°C caused a falsely
positive reaction at more than 8 U per 50 µL. Reactivity
with anti-Fya, -Fyb, -S, and -s disappeared at 1 U, but
reactivity with anti-M was not eliminated until 8 U.
Consequently, from the reactivity with anti-Fya, -Fyb, -S,
and -s, the optimal conditions for chymotrypsin
treatment were determined to be 4 U in Glycine-LISS,
pH 8, at 37°C for 30 minutes. Under these conditions,
treated RBCs were nonreactive not only with anti-Fya,
-Fyb, -S, and -s but also with anti-Xga, -Lua, and -Lub. In
addition, reactivity with anti-M, -K, -k, -Kpa, and -Kpb was
reduced (Table 1).
Optimal bromelin treatment conditions for M-MPHA
When RBCs were treated with bromelin at RT for
10 minutes with PBS at pH 6, the reactivity with anti-S
and -s did not disappear,but the reactivity with anti-Fya,
-Fyb, and -M completely disappeared at 0.13 U, 0.13 U,
and 0.27 U per 50 µL, respectively. Falsely positive
reactions occurred at more than 8.6 U. After RBC
treatment, either in PBS at pH 7 or pH 8, reactivity with
anti-S disappeared at 4.4 U, but anti-s was still reactive.
Based on the reactivity with anti-Fya, -Fyb, and -M and
the falsely positive reaction, the optimal conditions
were determined to be 2 U at pH 6, at RT for 10
minutes. Eight of nine one-stage bromelin-treated
falsely positive samples tested against bromelin-treated
RBCs by M-MPHA were detected with anti-IgM-
sensitized particles alone, and one was detected with
anti-IgG sensitized particles alone.
Optimal papain treatment conditions for M-MPHA
When RBCs were treated with papain in PBS at pH
6, 7, and 8 for 10 minutes at RT, reactivity with anti-Fya,
-Fyb, -M, -S, and -s was weakest at pH 6. (Table 2). In
more detail, when RBCs were treated at pH 8, their
reactivity with anti-Fya and -Fyb disappeared at 0.23 U
per 50 µL, but reactivity with anti-M, -S, and -s did not
disappear until 30 U. On the other hand, when RBCs
were treated at pH 6, the reactivity with anti-Fya, -Fyb,
-M, -S, and -s disappeared at 0.03, 0.03, 1.87, 0.94, and
7.5 U per 50 µL, respectively. When RBCs were treated
at pH 6.5, reactivity with anti-s did not disappear
regardless of treatment and incubation at 37°C for 30
Table 1. Reactivity of papain-, trypsin-, chymotrypsin-, and DTT-treated
RBCs with various antibodies
No. of samples detected versus treated RBCs
DTT Trypsin Papain Chymotrypsin
0.0125 M 320 U 16 U 4 U
pH=8 pH=8 pH=6 Gly-LISS pH=8
No. of 37˚C 37˚C RT 37˚C
Antibodies samples 30 min. 30 min. 10 min. 30 min.
D 10 10 10↑ 10↑ 10↑
C 10 10 10↑ 10↑ 10↑
E 10 10 10↑ 10↑ 10↑
e 10 10 10↑ 10↑ 10↑
c 10 10 10↑ 10↑ 10↑
S 4 4 4 0 0
s 4 4 4 0 0
M 2 2 0 0 1↓
Xga 3 3 0 0 0
Fya 9 9 9 0 0
Fyb 5 5 5 0 0
K 13 0 13 13↑ 7↓
k 6 0 6 6↑ 4↓
Kpa 5 0 5 5↑ 3↓
Kpb 9 0 9 9↑ 8↓
Jsb 4 0 4 4 4
Jka 12 12 12↑ 12↑ 12↑
Jkb 9 9 9↑ 9↑ 9↑
Lea 2 2 2↑ 2↑ 2↑
Lua 4 4 0 4 0
Lub 5 5 0 5 0
Dia 6 6 6 6 6
Jra 8 8 8↑ 8↑ 8↑
Rg 3 3 1↓ 1↓ 1↓
Wra 1 1 1↑ 1↑ 1↑
HLA related 5 5 5↑ 5↑ 5
Negative serum 20 0 0 0 0
↑Antibody reactivity was increased
↓Antibody reactivity was decreased
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minutes. Falsely positive reactions did not occur until
30 U at pH 6, 7, and 8 (Table 2). Consequently, based
on reactivity with anti-Fya, -Fyb, -M, -S, and -s, the optimal
conditions were determined to be 16 U per 50 µL at pH
6,at RT for 10 minutes. Under these conditions, treated
RBCs were nonreactive with anti-Fya, -Fyb, -M, -S, -s, and 
-Xga (Table 1). On the other hand, reactivity with anti-
D, -C, -E, -c, -e, -Jka, -Jkb, -Jra, -K, -k, -Kpa, -Kpb, -Lea, and HLA-
related antibodies increased (Table 1).
Reactivity of dried treated RBCs
RBCs were treated with papain, trypsin,
chymotrypsin, and DTT under various conditions and
vacuum dried.7 The reaction of these dried, treated
RBCs with various antibodies was evaluated. Optimal
conditions of trypsin and DTT for drying were the
same as for conventional RBCs, and the dried RBC
reactivity was the same as that of conventional treated
RBCs (Table 3).
A clear negative pattern could not be obtained with
the papain-treated dried RBCs that were treated at
more than 3.75 U. Consequently, for drying, the
optimal papain treatment condition was determined to
be 0.93 U per 50 µL. At this concentration, the reaction
of papain-treated dried RBCs with anti-Fya, -Fyb, -M, -S,
and -Xga was negative but reactivity with anti-s was not
completely eliminated. The optimal condition of
chymotrypsin treatment for drying could not be
determined, since a clear negative pattern could not be
obtained under conditions in which anti-Fya, -Fyb, -S, -s,
-M, and -Xga were negative.
Discussion
K, k, Kpa, Kpb, Jsb, Lua, and Lub antigens are
denatured by DTT because DTT disrupts the secondary
structure of proteins by reducing disulfide bonds.12,13
Both pH and temperature are important for DTT
treatment. The optimal condition in this study was
determined to be 0.0125 M DTT at pH 8, at 37°C for 30
minutes. Under these conditions, RBC reactivity with
anti-K, -k, -Kpa,
-Kpb, and -Jsb was eliminated, confirming that the
antigens were denatured. On the other hand, reactivity
with anti-Lua and -Lub showed the same maximum titer
when tested with 0.2 M DTT-treated RBCs and
untreated RBCs. The Lua and Lub antigenicity of these
treated RBCs did not appear to change, contrary to
some reports.14,15
Conditions of enzyme treatment are important for
RBC antigenicity. When RBCs were treated with
increasing concentrations of papain, Fya and Fyb
antigens were denatured first, S and M antigens were
denatured next, and the s antigen was denatured last.
Thus, certain antigens can be denatured selectively by
using different papain concentrations. Of course, not
only the enzyme concentration but also the pH was
important; e.g., at pH 6, M and S antigens disappeared
at 1.87 and 0.94 U per 50 µL papain treatment, but at
pH 6.5, they did not disappear even at 30 U (data not
shown). It has been reported that the S antigen is more
easily denatured than the s antigen by chymotrypsin
treatment,16 and the s antigen is more easily denatured
than the S antigen by ficin or papain treatment.17,18
Contrary to these reports, the S antigen in our study
seemed to be more easily denatured than the s antigen
by chymotrypsin, papain, and bromelin treatment.
Conditions for enzyme treatment of RBCs are also
important because overtreated RBCs can cause falsely
positive reactions. Comparing papain with bromelin,
falsely positive reactions seemed to occur less often
Table 2. Papain concentration (U per 50 µL) at which antibody reactivity
disappeared*
pH Anti-Fya Anti-Fyb Anti-M Anti-S Anti-s
6 0.03 0.03 1.87 1.87 7.5
7 0.06 0.06 † 0.94 †
8 0.23 0.23 † † †
*Treatment was done at RT for10 minutes 
†Did not disappear until 30 U
Table 3. Number of antibodies detected by enzyme- or DTT-treated dried
RBCs
No. of detected antibodies
DTT- Papain- Trypsin-
treated treated treated
No. Intact dried dried dried
Antibodies tested RBCs RBCs RBCs RBCs
D 1 1 1 1 1
C 1 1 1 1 1
E 1 1 1 1 1
e 1 1 1 1 1
c 1 1 1 1 1
S 4 4 4 0 4
s 4 4 4 4 4
M 1 1 1 0 0
Xga 1 1 1 0 0
Fya 5 5 5 0 5
Fyb 8 8 8 0 8
K 5 5 0 5 5
k 6 6 0 6 6
Kpa 5 5 0 5 5
Kpb 5 5 0 5 5
Jsb 4 4 0 4 4
Jka 4 4 4 4 4
Jkb 6 6 6 6 6
Lua 4 4 4 4 0
Lub 3 3 3 3 0
Negative serum 20 0 0 0 0
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with papain. The concentrations of papain and
bromelin needed to denature Fya and Fyb antigens were
the same as in the report of Mazda et al.,19 but papain
did not cause a falsely positive reaction even though
papain was used at fifteen times the concentration at
which bromelin caused a falsely positive reaction.
Because of this result, papain was used for drying RBCs
for M-MPHA-Dry.
The optimal enzyme treatment concentration was
different for testing dried RBCs. When drying RBCs
after chymotrypsin and papain treatment, a clear
negative pattern could not be obtained at the optimal
concentration for conventional RBCs. Enzyme
treatment causes reduction of a RBC’s charge and
density and modification of the membrane,20 the latter
caused by membrane-associated protein cleaving. It is
not difficult to presume that modification of RBC
membranes is different when comparing enzyme-
treated conventional RBCs and enzyme-treated, lysed,
and/or dried RBCs.
Falsely positive reactions with enzyme-treated
RBCs also sometimes occur with optimally treated
RBCs. These types of falsely positive reactions may be
caused by IgM agglutinins, because the falsely positive
samples, seen with optimally treated RBCs by the tube
test, were also detected only by anti-IgM-sensitized
particles in this study. To look at it another way, most
falsely positive reactions with enzyme-treated RBCs are
not detected by M-MPHA, if anti-IgG sensitized particles
are used for irregular antibody screening. On the other
hand, falsely positive reactions with over-treated RBCs
were detected by anti-IgG-sensitized particles. So the
cause of these two types of enzyme falsely positive
reactions seems to be different. We presume one is
caused by nonspecific binding of IgG in the serum and
the other by specific IgM binding.
Other RBC treatment agents, such as EDTA/acid21
or chloroquine,22 are also routinely used for RBC treat-
ment. These agents could not be used for M-MPHA and
M-MPHA Dry, since a clear negative pattern could not
be obtained. (Data not shown).
In conclusion, enzyme or DTT treatment of
adherent RBCs assessed by M-MPHA provides a simple
antibody identification test with minimized falsely
positive reactions. Furthermore, the drying technique
of treated RBCs provides a more convenient and simple
antibody identification tool since dried RBCs can be
stored for a long period.
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